PD-1 TurboCAR-T cell therapy(Allogene Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePD-1 TurboCAR-T cell therapy(Allogene Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-PD-1

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAllogene Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A